Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Antibe Therapeutics, Inc. (OTC: ATBPF).

Full DD Report for ATBPF

You must become a subscriber to view this report.


Recent News from (OTC: ATBPF)

Antibe Therapeutics Announces Strategic Licensing Deal for Lead Drug in South Korea
License includes C$13 million in non-dilutive milestone payments and a double-digit royalty to Antibe Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has entered i...
Source: Business Wire
Date: September, 05 2018 07:00
Antibe Therapeutics Reports Q1 2019 Interim Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Wednesday, August 29 th for the fiscal quarter ended June 30, 2018. The Company’s unaudited fiscal Q1 2019 condensed interim consolidated financia...
Source: Business Wire
Date: August, 29 2018 18:45
Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has prepared a comprehensive report of the recently-completed Phase 2B study for its lead drug, ATB-...
Source: Business Wire
Date: August, 29 2018 07:30
Your Daily Pharma Scoop: Puma Progresses, Kala In Phase 3, Teva Fails
Stocks in the News: PBYI, KALA Puma Bio's Nerlynx marketing application in Canada under review Puma Biotechnology's ( PBYI ) New Drug Submission (‘NDS) for NERLYNX ( neratinib ) for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer is...
Source: SeekingAlpha
Date: August, 02 2018 06:35
Antibe's timeline for mid-stage study of ATB-346 extended, metabolism protocol added
In a update to investors, Antibe Therapeutics ( OTCQB:ATBPF ) announces that its Phase 2 clinical trial evaluating lead candidate ATB-346 will now include a metabolism protocol in addition to the dose-ranging efficacy portion. More news on: Antibe Therapeutics, Inc., Healthcare stocks ne...
Source: SeekingAlpha
Date: July, 31 2018 07:59
Antibe Therapeutics Provides Clinical Development Update on Its Lead Drug
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to provide an update on its clinical development activities for its lead drug, ATB-346. The Phase 2 dose-ranging, ...
Source: Business Wire
Date: July, 31 2018 07:00
Antibe Completes Share Issuance in Connection with Citagenix Credit Facility
Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) announces that further to its release of June 29, 2018, it has issued to Bloom Burton Healthcare Lending Trust (“BBHLT”) 578,572 common shares in the capital of Company (&...
Source: Business Wire
Date: July, 06 2018 19:15
Your Daily Pharma Scoop: Eagle Gets New Patent, Ocular Refiles NDA, Antibe's Phase 2b Data Announced
Stocks in News: Eagle Pharma nabs new U.S. patent covering Bendeka Discussion : Eagle Pharmaceuticals Inc. ( EGRX ) is a specialty pharmaceutical company focused on developing and commercializing injectable products for oncology and critical care segments. The lead candidate of the ...
Source: SeekingAlpha
Date: July, 05 2018 14:59
Antibe releases secondary endpoint data from mid-stage study of lead drug ATB-346
Antibe Therapeutics ( OTCQB:ATBPF ) announces secondary endpoint data from its Phase 2b gastrointestinal safety study of lead candidate ATB-346. The incidence of gastric or duodenal ulcers at least 5 mm in diameter with unequivocal depth was 0% for ATB-346 compared to 24% for naproxen, the...
Source: SeekingAlpha
Date: July, 03 2018 07:41
Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce the secondary endpoint data from the recent Phase 2B gastrointestinal (“GI”) safety study fo...
Source: Business Wire
Date: July, 03 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-130.18960.18550.19220.18552,800
2018-12-120.18010.1960.1960.1838,000
2018-12-110.1840.18530.18530.177323,762
2018-12-100.18910.18910.18910.18911,550
2018-12-070.190.19230.19820.1825586,577

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-132,3002,80082.1429Short
2018-12-1226,00038,00068.4211Short
2018-12-1114,00023,76258.9176Short
2018-12-101,5501,550100.0000Short
2018-12-0719,50086,57722.5233Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ATBPF.


About Antibe Therapeutics, Inc. (OTC: ATBPF)

Logo for Antibe Therapeutics, Inc. (OTC: ATBPF)

Antibe is a commercial stage pharmaceutical company focused on pain, inflammation and regenerative medicine. Antibe s lead drug, ATB , targets the global need for a safer non steroidal anti inflammatory drug NSAID for treating chronic pain and inflammation with non addictive medication. Antibe s subsidiary, Citagenix Inc. Citagenix , is a leader in Canada in the sales and marketing of tissue regenerative products servicing the dental and orthopaedic marketplaces. Since its inception in , Citagenix has become an important source of knowledge and experience in the Canadian medical device industry. Citagenix has grown a comprehensive portfolio of high quality, branded biologics and medical devices that promote bone regeneration. Citagenix is active in countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships.

 

 

 

Current Management

  • Daniel Legault / CEO
  • John Wallace / CSO
  • Alain Wilson / CFO
  • Scott Curtis / VP, Business Development
  • David Vaughan / Chief Development Officer
  • Beth Chin / Finance Manager
  • Walt Macnee / Chairman
  • Roderick Flower /
  • Daniel Legault /
  • Samira Sakhia /
  • John Wallace /

Current Share Structure

  • Market Cap: $41,059,615 - 03/16/2018
  • Issue and Outstanding: 162,967,313 - 12/31/2017
  • Float: 121,474,519 - 09/08/2017

 


Recent Filings from (OTC: ATBPF)

Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Nine Months ended December 31, 2017
Filing Type: Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Nine MonFiling Source: OTC Markets
Filing Date: February, 27 2018
Interim Financial Report - Interim Consolidated Financial Statements For the Three and Nine Months ended December 31, 2017 and 2016
Filing Type: Interim Financial Report - Interim Consolidated Financial Statements For the Three and Nine Months eFiling Source: OTC Markets
Filing Date: February, 27 2018
Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Six Months ended September 30, 2017
Filing Type: Management Discussion and Analysis - Management's Discussion and Analysis for the Three and Six MontFiling Source: OTC Markets
Filing Date: November, 29 2017
Interim Financial Report - Interim Consolidated Financial Statements For the Three and Six Months ended September 30, 2017 and 2016
Filing Type: Interim Financial Report - Interim Consolidated Financial Statements For the Three and Six Months enFiling Source: OTC Markets
Filing Date: November, 29 2017
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: September, 08 2017

 

 


Daily Technical Chart for (OTC: ATBPF)

Daily Technical Chart for (OTC: ATBPF)


Stay tuned for daily updates and more on (OTC: ATBPF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATBPF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATBPF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATBPF and does not buy, sell, or trade any shares of ATBPF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/